AAAAAA

   
Results: 1-16 |
Results: 16
THE SAFETY AND EFFICACY OF OXCARBAZEPINE AS ADJUNCTIVE THERAPY IN CHILDREN - AN OPEN-LABEL STUDY
Authors: MANDELBAUM DE KUGLER SL WENGER E SACHDEO R
Citation: De. Mandelbaum et al., THE SAFETY AND EFFICACY OF OXCARBAZEPINE AS ADJUNCTIVE THERAPY IN CHILDREN - AN OPEN-LABEL STUDY, Annals of neurology, 44(3), 1998, pp. 63-63
DOUBLE-BLIND RANDOMIZED TRIAL OF TRAMADOL FOR THE TREATMENT OF THE PAIN OF DIABETIC NEUROPATHY
Authors: HARATI Y GOOCH C SWENSON M EDELMAN S GREENE D RASKIN P DONOFRIO P CORNBLATH D SACHDEO R SIU CO KAMIN M
Citation: Y. Harati et al., DOUBLE-BLIND RANDOMIZED TRIAL OF TRAMADOL FOR THE TREATMENT OF THE PAIN OF DIABETIC NEUROPATHY, Neurology, 50(6), 1998, pp. 1842-1846
SAFETY AND EFFICACY OF OXCARBAZEPINE MONOTHERAPY
Authors: SACHDEO R BEYDOUN A SCHACHTER S VAZQUEZ B SCHAUL N MESENBRINK P DSOUZA J
Citation: R. Sachdeo et al., SAFETY AND EFFICACY OF OXCARBAZEPINE MONOTHERAPY, Neurology, 50(4), 1998, pp. 4005-4005
SENSORY SLEEP STARTS
Authors: SANDER HW GEISSE H QUINTO C SACHDEO R CHOKROVERTY S
Citation: Hw. Sander et al., SENSORY SLEEP STARTS, Journal of Neurology, Neurosurgery and Psychiatry, 64(5), 1998, pp. 690-690
SENSORY SLEEP STARTS MISDIAGNOSED AS SIMPLE OR COMPLEX PARTIAL SEIZURES
Authors: GEISSE H QUINTO C SACHDEO R SANDER HW CHOKROVERTY S
Citation: H. Geisse et al., SENSORY SLEEP STARTS MISDIAGNOSED AS SIMPLE OR COMPLEX PARTIAL SEIZURES, Neurology, 48(3), 1997, pp. 4116-4116
TOLERABILITY AND PHARMACOKINETICS OF MONOTHERAPY FELBAMATE DOSES OF 1,200-6,000 MG DAY IN SUBJECTS WITH EPILEPSY/
Authors: SACHDEO R NARANGSACHDEO SK SHUMAKER RC PERHACH JL LYNESS WH ROSENBERG A
Citation: R. Sachdeo et al., TOLERABILITY AND PHARMACOKINETICS OF MONOTHERAPY FELBAMATE DOSES OF 1,200-6,000 MG DAY IN SUBJECTS WITH EPILEPSY/, Epilepsia, 38(8), 1997, pp. 887-892
EFFICACY OF TOPRIMATE IN LENNOX-GASTAUT SYNDROME
Authors: KUGLER SL SACHDEO R WENGER E MANDELBAUM DE
Citation: Sl. Kugler et al., EFFICACY OF TOPRIMATE IN LENNOX-GASTAUT SYNDROME, Annals of neurology, 40(2), 1996, pp. 68-68
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE-STUDY OF GABAPENTIN (CI-945) ADMINISTERED AS AN INITIAL DOSAGE OF 900 MG DAY VERSUS A DOSAGE TITRATED TO 900 MG/DAY OVER 3 DAYS/
Authors: FISHER RS PENOVICH P PELLOCK J SACHDEO R
Citation: Rs. Fisher et al., A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE-STUDY OF GABAPENTIN (CI-945) ADMINISTERED AS AN INITIAL DOSAGE OF 900 MG DAY VERSUS A DOSAGE TITRATED TO 900 MG/DAY OVER 3 DAYS/, Neurology, 46(2), 1996, pp. 24005-24005
SAFETY AND EFFICACY OF BID AND QID DOSING WITH TIAGABINE HCL VERSUS PLACEBO AS ADJUNCTIVE TREATMENT FOR PARTIAL SEIZURES
Authors: SACHDEO R LEROY R KRAUSS G GREEN P DRAKE M LEPPIK I SHU V RINGHAM G SOMMERVILLE K
Citation: R. Sachdeo et al., SAFETY AND EFFICACY OF BID AND QID DOSING WITH TIAGABINE HCL VERSUS PLACEBO AS ADJUNCTIVE TREATMENT FOR PARTIAL SEIZURES, Neurology, 45(4), 1995, pp. 202-202
DOSE-RANGING STUDY TO DETERMINE THE TOLERABILITY OF TIAGABINE HCL ADMINISTERED AS MONOTHERAPY
Authors: SCHACHTER S WANNAMAKER B CAHILL W SACHDEO R HEARELL K SHU V HIGHTOWER B SOMMERVILLE K
Citation: S. Schachter et al., DOSE-RANGING STUDY TO DETERMINE THE TOLERABILITY OF TIAGABINE HCL ADMINISTERED AS MONOTHERAPY, Epilepsia, 36, 1995, pp. 148-148
LONG-TERM SAFETY OF TIAGABINE HCL
Authors: LEPPIK IE SACHDEO R ALTO G RINGHAM G PIXTON G KARDATZKE D SOMMERVILLE K
Citation: Ie. Leppik et al., LONG-TERM SAFETY OF TIAGABINE HCL, Epilepsia, 36, 1995, pp. 149-149
SINGLE-CENTER TOPIRAMATE MONOTHERAPY TRIAL
Authors: SACHDEO R
Citation: R. Sachdeo, SINGLE-CENTER TOPIRAMATE MONOTHERAPY TRIAL, Epilepsia, 36, 1995, pp. 151-152
TOPIRAMATE - NEUROPSYCHOMETRIC ASSESSMENTS
Authors: BROOKS J SACHDEO R LIM P
Citation: J. Brooks et al., TOPIRAMATE - NEUROPSYCHOMETRIC ASSESSMENTS, Epilepsia, 36, 1995, pp. 273-273
TOPIRAMATE-TEGRETOL INTERACTION
Authors: SACHDEO S SACHDEO R DOOSE DR KRAMER LD
Citation: S. Sachdeo et al., TOPIRAMATE-TEGRETOL INTERACTION, Neurology, 44(4), 1994, pp. 10000205-10000205
TOLERABILITY AND STEADY-STATE PHARMACOKINETICS OF FELBAMATE FOLLOWINGMONO-THERAPY OVER THE ORAL DOSE RANGE OF 3600 TO 6000 MG DAY IN SUBJECTS WITH EPILEPSY/
Authors: SACHDEO R SACHDEO S HOWARD J DIX R SHUMAKER R PERHACH J ROSENBERG A
Citation: R. Sachdeo et al., TOLERABILITY AND STEADY-STATE PHARMACOKINETICS OF FELBAMATE FOLLOWINGMONO-THERAPY OVER THE ORAL DOSE RANGE OF 3600 TO 6000 MG DAY IN SUBJECTS WITH EPILEPSY/, Neurology, 44(4), 1994, pp. 10000296-10000296
FELBAMATE MONOTHERAPY - CONTROLLED TRIAL IN PATIENTS WITH PARTIAL-ONSET SEIZURES (REPRINTED FROM ANNALS NEUROLOGY, VOL 32, PG 386, 1992)
Authors: SACHDEO R KRAMER LD ROSENBERG A SACHDEO S
Citation: R. Sachdeo et al., FELBAMATE MONOTHERAPY - CONTROLLED TRIAL IN PATIENTS WITH PARTIAL-ONSET SEIZURES (REPRINTED FROM ANNALS NEUROLOGY, VOL 32, PG 386, 1992), Hospital formulary, 28, 1993, pp. 21-28
Risultati: 1-16 |